Related Experiment Video
Updated: Mar 5, 2026
Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles
Published on: December 1, 2016
Treatment Rationale and Design for J-AXEL: A Randomized Phase 3 Study Comparing Nab-Paclitaxel With Docetaxel in
Yasuto Yoneshima1, Satoshi Morita2, Masahiko Ando3
1Division of Respiratory Medicine, Kyushu Central Hospital of the Mutual Aid Association of Public School Teachers, Fukuoka, Japan; Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Background:
Nanoparticle albumin-bound (nab) paclitaxel is a promising new therapeutic agent for all histologic types of non-small-cell lung cancer (NSCLC). We recently performed a phase 2 study of weekly nab-paclitaxel in patients with previously treated advanced NSCLC, finding promising activity and acceptable toxicity for this regimen. We have now designed a randomized phase 3 intergroup study (J-AXEL, UMIN000017487) to examine the clinical benefit and safety of nab-paclitaxel compared to docetaxel in patients with previously treated advanced NSCLC.
Patients And Methods:
Patients are randomized to receive either docetaxel (60 mg/m2 on day 1 every 3 weeks, control arm) or nab-paclitaxel (100 mg/m2 on days 1, 8, and 15 every 3 weeks, experimental arm), with each drug being administered until disease progression or unacceptable toxicity. The study will evaluate the noninferiority of nab-paclitaxel relative to docetaxel for the primary end point of overall survival.
Conclusion:
If the primary objective is achieved, this study will provide evidence for a new alternative treatment option for patients with previously treated advanced NSCLC.
Insights
This phase 3 trial compares nanoparticle albumin-bound paclitaxel (nab-paclitaxel) to docetaxel in advanced non-small-cell lung cancer (NSCLC) patients. It aims to establish nab-paclitaxel as a safe and effective alternative treatment option.
Area of Science:
- Oncology
- Pharmacology
Background:
- Nanoparticle albumin-bound (nab) paclitaxel shows promise for non-small-cell lung cancer (NSCLC).
- Previous phase 2 studies indicated promising activity and acceptable toxicity of weekly nab-paclitaxel in advanced NSCLC.
- A phase 3 study is designed to compare nab-paclitaxel with docetaxel in previously treated advanced NSCLC patients.
Purpose of the Study:
- To evaluate the clinical benefit and safety of nab-paclitaxel compared to docetaxel.
- To assess the noninferiority of nab-paclitaxel relative to docetaxel for overall survival.
Main Methods:
- A randomized phase 3 intergroup study (J-AXEL).
- Patients receive either docetaxel (60 mg/m² every 3 weeks) or nab-paclitaxel (100 mg/m² on days 1, 8, 15 every 3 weeks).
- Treatment continues until disease progression or unacceptable toxicity.
Main Results:
- The primary endpoint is to evaluate the noninferiority of nab-paclitaxel versus docetaxel for overall survival.
Conclusions:
- If noninferiority is demonstrated, nab-paclitaxel will be established as a new alternative treatment option.
- This study provides evidence for improved therapeutic options in previously treated advanced NSCLC.
More Related Videos
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
08:41Carotid Artery Infusions for Pharmacokinetic and Pharmacodynamic Analysis of Taxanes in Mice
Published on: October 27, 2014